Conference Coverage

Beware of polypharmacy in patients taking warfarin


 

REPORTING FROM THSNA 2018


The researchers reported that 9,885 prescriptions were tabulated for the study population, which translated into a per patient average of 8.8 concurrent active prescription drugs, independent of age. They observed an age-dependent increase in the number of concurrent drugs that peaked at 9.9 among patients aged 70-74 years, and tapered off in those older than age 75. One patient in the 70- to 74-year-old age group was on 28 active prescriptions.

“If you’re on 28 pills, your chance of a bleeding complication is high,” Dr. Jacobson said. “We try to be rigorous with all of our patients on education. With these patients, slow the conversation down more. Have a family member come in with them and go into more detail.”


He added that the maximum number of concurrent prescriptions for any single patient in each age bracket tended to be two to three times higher than that of the average patient.

Dr. Jacobson acknowledged certain limitations of the study, including its single-center design and relatively small sample size. There was also no comparison available as to the number of concurrent prescriptions for patients not receiving warfarin. He reported having no financial disclosures.

[email protected]

SOURCE: Jacobson M et al. THSNA 2018. Poster 2.

Pages

Recommended Reading

Idarucizumab reverses anticoagulation effects of dabigatran
The Hospitalist
Rivaroxaban lowers cardiovascular risk but increases bleeding risk
The Hospitalist
Triple therapy in question
The Hospitalist
VIDEO: Anticoagulant underprescribing common, jeopardizing atrial fib patients
The Hospitalist
Controversy surrounds calf vein thrombosis treatment
The Hospitalist
Rivaroxaban versus warfarin in mild acute ischemic stroke secondary to atrial fibrillation
The Hospitalist
Anticoagulation use in new-onset secondary atrial fibrillation
The Hospitalist
A simplified risk prediction model for patients presenting with acute pulmonary embolism
The Hospitalist
Ticagrelor noninferior to clopidogrel in terms of major bleeds in STEMI
The Hospitalist
VIDEO: Dabigatran effective for myocardial injury after noncardiac surgery
The Hospitalist
   Comments ()